Category: Biolase Technology Inc.
Two heads are better than 1 at Mindray Medical, which appointed chief strategic officer Cheng Minghe as co-CEO alongside chief Li Xiting.
Mindray Medical (NYSE:MR) chief Li Xiting will share the corner office, so to speak, with new co-CEO Cheng Minghe, who takes the new title in addition to continuing as the company's chief strategic officer.
Cheng is one of the founders of the Shenzhen, China-based company, and has worked in various roles since 1991.
Biolase CEO Federico Pignatelli, who made waves with his commitment to a $1 salary, denies rumors that he is stepping down.
Biolase (NSDQ:BLTI) issued a message to concerned investors, quashing rumors of CEO Federico Pignatelli's imminent departure and asserting his continued leadership of the dental laser company.
The FDA clears Biolase's WaterLase iPlus tissue laser in the U.S.
Biolase (NSDQ:BIOL) won 510(k) clearance from the FDA for its WaterLase iPlus, a laser used for soft-tissue orthopedic procedures.
The clearance opens up a $2.6 billion market opportunity for the WaterLase device, according to a company statement.
California medical device maker Biolase won FDA clearance to market its EPIC 10S soft tissue diode laser for more than 80 indications.
Dental devices maker Biolase (NSDQ:BIOL) touted FDA clearance for its EPIC 10S soft tissue diode laser, which the company can now market for more than 80 indications spanning 19 medical markets.
The FDA placed Class I risk status on Ad-Tech Medical Instrument Corp.'s recall of its Macro Micro Subdural Electrodes over concerns that the brain implants may cause injury to the brain.
MASSDEVICE ON CALL — Federal healthcare regulators gave Ad-Tech Medical Instrument Corp.'s wide-reaching brain implant recall Class I status, the highest-risk category for medical device recalls.
Late last year the Wisconsin-based medical device maker recalled its Macro Micro Subdural Electrodes over concerns that the implanted devices could cause damage to the brain.
Biolase wins a nod from the FDA to expand its soft-tissue laser to 19 different markets.
Biolase (NSDQ:BIOL) won FDA approval for the use of its 940nm Diolase 10 laser in a range of different markets. The federal watchdog agency also cleared 80 new procedures for the device.
The Irvine, Ca-based dental laser company said it can now sell into more than 20 new markets, including ear, nose and throat, arthroscopy, dermatology, plastic surgery and ophthalmology.